<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01187186</url>
  </required_header>
  <id_info>
    <org_study_id>1941-CL-0063</org_study_id>
    <nct_id>NCT01187186</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941</brief_title>
  <official_title>A Phase 1, Open-Label, Single-Dose Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics (PK) and safety following oral
      administration of ASP1941 in subjects with moderate hepatic impairment and in subjects with
      normal hepatic function based on the Child-Pugh Classification (CPC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study drug will be orally administered on Day 1. Subjects will be admitted to the clinic
      until completion of clinic discharge procedures on Day 7 with an outpatient follow-up visit
      6-9 days after clinic discharge.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic variables used to assess the effect of hepatic function through analysis of blood samples</measure>
    <time_frame>7 days following study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables used to assess the effect of hepatic impairment through analysis of blood and urine samples</measure>
    <time_frame>7 days following study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Liver Disease</condition>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Moderate Hepatic Impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Hepatic Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Normal Hepatic Function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1941</intervention_name>
    <description>oral</description>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Normal Hepatic Function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with Moderate Hepatic Impairment

               -  Agrees to practice highly effective birth control until 7 days post dose. If
                  female, two years post-menopausal, surgically sterile, and not pregnant or
                  lactating

               -  Weights at least 45 kg

               -  Body mass index between 18 and 34 kg/m2

               -  Meets criteria for moderate hepatic impairment defined by Child-Pugh method

          -  Subjects with Normal Hepatic Function

               -  Agrees to practice highly effective birth control until 7 days post dose. If
                  female, two years post-menopausal, surgically sterile, and not pregnant or
                  lactating

               -  Weights at least 45 kg

               -  Body mass index between 18 and 34 kg/m2

               -  Must have normal hepatic function defined by Child-Pugh method

        Exclusion Criteria:

          -  Subjects with Moderate Hepatic Impairment

               -  Has history or presence of biliary obstruction or biliary disease, hepatic
                  encephalopathy, advanced ascites, portal hypertension, esophageal /gastric
                  variceal bleeding, hepatocellular carcinoma, previous liver transplantation.

               -  Has severe or moderate renal dysfunction

               -  Known to be human immunodeficiency virus (HIV) positive

               -  Has clinically significant history or presence of illness, malignancy or
                  immunodeficiency

               -  Has had a blood transfusion or donated / lost 450 mL of blood or more within 60
                  days of study drug administrations or donated plasma within 7 days prior to
                  clinical check-in

               -  Has history of alcoholism or drug/chemical/substance abuse within past 2 years

          -  Subjects with Normal Hepatic Function

               -  Has severe or moderate renal dysfunction

               -  Known to be human immunodeficiency virus (HIV) positive

               -  Has clinically significant history or presence of illness, malignancy or
                  immunodeficiency

               -  Has had a blood transfusion or donated / lost 450 mL of blood or more within 60
                  days of study drug administrations or donated plasma within 7 days prior to
                  clinical check-in

               -  Has history of alcoholism or drug/chemical/substance abuse within past 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2010</study_first_submitted>
  <study_first_submitted_qc>August 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2010</study_first_posted>
  <last_update_submitted>October 5, 2010</last_update_submitted>
  <last_update_submitted_qc>October 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sr Manager Clinical Trials Registry</name_title>
    <organization>Astellas Pharma Global Development</organization>
  </responsible_party>
  <keyword>Liver disease</keyword>
  <keyword>ASP1941</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

